Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 BPH NX02-0020 Repeat Injection U.S. Study
Nymox Pharmaceutical Corporation (Nasdaq: NYMX) provided an update today on the Company's Phase 3 NX02-0020 repeat injection U.S. study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The recent Safety Monitoring Committee meeting was favorable and indicated no significant safety concerns for the trial to date. Patient recruitment and trial activities for this U.S. Phase 3 Study are nearing completion at well-known urology investigative sites throughout the U.S.
NX-1207 has been shown to improve the signs and symptoms of BPH, producing improvements which in previous studies have reached statistical significance compared to double-blinded placebo and study controls. A single administration of NX-1207 2.5 mg has produced on average improvements in the standardized BPH symptom score (8-10 points at 90 days) that were approximately double that reported for currently approved BPH drugs (3-5 points). The drug is administered by a urologist in an office setting and involves little or no pain or discomfort. NX-1207 has not been found to have the sexual, blood pressure, or other side effects of the approved drugs. Follow-up studies have shown clinical efficacy effects in many men lasting up to 7½ years after a single treatment.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.